View More Recent Stories

Jun 25, 2024 05:56AM AstraZeneca (AZN) Issues Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer

Jun 25, 2024 05:56AM AstraZeneca (AZN) reports Tagrisso plus chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Jun 20, 2024 06:09AM AstraZeneca (AZN) announces Truqap plus Faslodex approved in the EU

Jun 18, 2024 06:09AM AstraZeneca (AZN) announces CAPItello-290 Phase III trial did not meet endpoints

Jun 17, 2024 07:03AM AstraZeneca (AZN) announces IMFINZI plus chemotherapy approved in the US

Jun 10, 2024 06:03AM AstraZeneca (AZN): TAGRISSO granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Jun 10, 2024 04:36AM AstraZeneca (AZN) announces Tagrisso granted FDA Priority Review for patients with unresectable, Stage III EGFR-mutated lung cancer

View More Recent Stories